Skip to content
NOWCAST 바카라게임 온라인 바카라 게임 5 Today
Watch on Demand
Advertisement

FDA approves new nasal spray to treat migraine headaches in adults, Pfizer says

FDA approves new nasal spray to treat migraine headaches in adults, Pfizer says
*** new study has revealed 52% of us suffer from some form of *** headache disorder. Each year, *** research group of scientists led by epidemiologists from the Norwegian University of Science and Technology study general headaches, migraine and tension type headaches. In summarizing studies from 1961 to the end of 2020 the data revealed that global prevalence for migraines is 14% and 26% for tension type head. The authors state each day 15.8% of the world's population had *** headache. The researchers also discovered that headaches were more common in females than in males. Migraines proved the largest difference between the genders common in 17% of females and only 8.6% in males. Women also reported headaches as an ongoing health issue. 6% of females reported they had *** headache on 15 or more days per month. 2.9% of males reported the same. According to the authors, the apparent increase in migraine prevalence over time maybe real, perhaps related to environmental, physical behavioral or psychological changes, but more probably it has to do with the methodological developments over the years, leading to better techniques of access and engagement and improve diagnostic instruments
Advertisement
FDA approves new nasal spray to treat migraine headaches in adults, Pfizer says
The U.S. Food and Drug Administration approved a new nasal spray as a rapid treatment for migraine pain in adults.The nasal spray zavegepant, sold as Zavzpret, may relieve pain and other bothersome migraine symptoms as soon as 15 minutes after use, drugmaker Pfizer said in a news release. The drug is expected to be available in pharmacies in July 2023, the company said.There are already a number of different types of medications available to treat migraines, including several kinds of nasal sprays. Zavzpret is the first to work by blocking the calcitonin gene-related peptide, CGRP, a protein that is released in the brain that contributes to inflammation. Several pills block CGRP, but many people with migraines experience significant nausea and can't tolerate medications they have to swallow.Zavzpret is also an alternative for people who have heart disease or other conditions that prevent them from being able to safely use other kinds of migraine treatments.In two studies where people with migraines didn't know if they were getting the drug or a placebo, Zavzpret was more effective at relieving migraine pain within two hours compared with a nasal spray without any active ingredients.In one study published in the journal The Lancet Neurology, about 24% of people who took a single 10-milligram dose of Zavzpret reported they had no pain two hours later, compared with 15% of the group who got a nasal spray without any active ingredients, a difference that was statistically significant. The main side effect reported in the study was an altered sense of taste, which affected about 1 in 5 people who took the drug. Other side effects were nasal discomfort and nausea."When a migraine hits, it has a significant negative impact on a person's daily life," Dr. Kathleen Mullin, the associate medical director at New England Institute for Neurology & Headache who has studied the drug, said in the news release from Pfizer. "Among my migraine patients, one of the most important attributes of an acute treatment option is how quickly it works. As a nasal spray with rapid drug absorption, Zavzpret offers an alternative treatment option for people who need pain relief or cannot take oral medications due to nausea or vomiting, so they can get back to normal function quickly."Migraines are estimated to affect more than 10% of people globally, and they're about three times more common in women than in men. They often involve throbbing pain in the head that can last for hours or days and may involve sensitivity to light or sound, nausea, vomiting or visual disturbances.

The U.S. Food and Drug Administration approved a new nasal spray as a rapid treatment for migraine pain in adults.

The nasal spray zavegepant, sold as Zavzpret, may relieve pain and other bothersome migraine symptoms as soon as 15 minutes after use, drugmaker Pfizer said in a news release. The drug is expected to be available in pharmacies in July 2023, the company said.

Advertisement

There are already a number of different types of medications available to treat migraines, including several kinds of nasal sprays. Zavzpret is the first to work by blocking the calcitonin gene-related peptide, CGRP, a protein that is released in the brain that contributes to inflammation. Several pills block CGRP, but many people with migraines experience significant nausea and can't tolerate medications they have to swallow.

Zavzpret is also an alternative for people who have heart disease or other conditions that prevent them from being able to safely use other kinds of migraine treatments.

In two studies where people with migraines didn't know if they were getting the drug or a placebo, Zavzpret was more effective at relieving migraine pain within two hours compared with a nasal spray without any active ingredients.

In one study published in the journal , about 24% of people who took a single 10-milligram dose of Zavzpret reported they had no pain two hours later, compared with 15% of the group who got a nasal spray without any active ingredients, a difference that was statistically significant. The main side effect reported in the study was an altered sense of taste, which affected about 1 in 5 people who took the drug. Other side effects were nasal discomfort and nausea.

Newly approved migraine drug, nasal spray Zavzpret, from Pfizer.
Courtesy Pfizer
Zavzpret nasal spray

"When a migraine hits, it has a significant negative impact on a person's daily life," Dr. Kathleen Mullin, the associate medical director at New England Institute for Neurology & Headache who has studied the drug, said in the news release from Pfizer. "Among my migraine patients, one of the most important attributes of an acute treatment option is how quickly it works. As a nasal spray with rapid drug absorption, Zavzpret offers an alternative treatment option for people who need pain relief or cannot take oral medications due to nausea or vomiting, so they can get back to normal function quickly."

are estimated to affect more than 10% of people globally, and they're about three times more common in women than in men. They often involve throbbing pain in the head that can last for hours or days and may involve sensitivity to light or sound, nausea, vomiting or visual disturbances.